Efficacy and Safety of the Chinese Herbal Compound TJAOA101 in Treating Diminished Ovarian Reserve: A Protocol for Multicenter, Prospective, and Pre-Post Study

Abstract

Objective

Diminished ovarian reserve (DOR) can lead to early menopause, poor fecundity, and an increased risk of disorders such as osteoporosis, cardiovascular disease, and cognitive impairment, seriously affecting the physical and mental health of women. There is still no safe and effective strategy or method to combat DOR. We have developed a novel Chinese herbal formula, Tongji anti-ovarian aging 101 (TJAOA101), to treat DOR. However, its safety and efficacy need to be further validated.

Methods

In this prospective and pre-post clinical trial, 100 eligible patients aged 18–45 diagnosed with DOR will be recruited. All participants receive TJAOA101 twice a day for 3 months. Then, comparisons before and after treatment will be analyzed, and the outcomes, including anti-mullerian hormone (AMH) and follicle-stimulating hormone (FSH) levels and the antral follicle count (AFC), the recovery rate of menopause, and the Kupperman index (KMI), will be assessed at baseline, every month during medication (the intervention period), and 1, 3 months after medication (the follow-up period). Assessments for adverse events will be performed during the intervention and follow-up periods.

Conclusion

A multicenter, prospective study will be conducted to further confirm the safety and efficacy of TJAOA101 in treating DOR and to provide new therapeutic strategies for improving the quality of life in DOR patients.

Keywords

diminished ovarian reserve / Chinese herbs / TJAOA101 / multicenter study / study protocol

References

[1] ZhangJ, ChenQ, DuD, et al.. Can ovarian aging be delayed by pharmacological strategies?. Aging, 2019, 11(2): 817-832

[2] MillsEG, YangL, NielsenMF, et al.. The Relationship Between Bone and Reproductive Hormones Beyond Estrogens and Androgens. Endocr Rev, 2021, 42(6): 691-719

[3] ZhaoL, WoodyS, ChhibberA. Estrogen receptor β in Alzheimer’s disease: From mechanisms to therapeutics. Ageing Res Rev, 2015, 24: 178-190

[4] SalamaM, WinklerK, MurachK, et al.. Female fertility loss and preservation: threats and opportunities. Ann Oncol, 2013, 24(3): 598-608

[5] ZhangQ, LiangJ, ZhouY. Network pharmacology analysis of molecular targets and related mechanisms of Guizhi decoction in treating of menopausal syndrome. Medicine, 2022, 101(29): e29453.

[6] YangX, XiaoH, ZengY, et al.. Tianwang Buxin Granules Influence the Intestinal Flora in Perimenopausal Insomnia. BioMed Res Int, 2021, 2021: 9979511

[7] LanJ, WuC, LiangW, et al.. An Effective Treatment of Perimenopausal Syndrome by Combining Two Traditional Prescriptions of Chinese Botanical Drugs. Front Pharmacol, 2021, 12: 744409

[8] WangYP, YuQ. The treatment of menopausal symptoms by traditional Chinese medicine in Asian countries. Climacteric, 2021, 24(1): 64-67

[9] XuZ, RuanX, XuX, et al.. Efficacy and safety of Zi Gui Nv Zhen(®) capsules used in TCM for fertility preservation in patients with diminished ovarian reserve. Gynecol Endocrinol, 2022, 38(1): 73-77

[10] MaK, WuJX, ZhangHX, et al.. Clinical efficacy of Bushen Huoxue Culuan Formula in treatment of infertility caused by diminished ovarian reserve due to kidney deficiency and blood stasis. Zhongguo Zhong Yao Za Zhi (Chinese), 2021, 46(11): 2644-2649

[11] JiangM, WangW, ZhangJ, et al.. Protective Effects and Possible Mechanisms of Actions of Bushen Cuyun Recipe on Diminished Ovarian Reserve Induced by Cyclophosphamide in Rats. Front Pharmacol, 2020, 11: 546

[12] Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril, 2020, 114(6): 1151-1157

[13] WuJ, ZhuX, HeJ, et al.. Clinical Value of Three-Dimensional Transvaginal Ultrasound in Diagnosis of Endometrial Receptivity and Ovarian Function in Patients with Infertility. Comput Math Meth Med, 2022, 2022: 8438131

[14] NappiRE, ChedrauiP, LambrinoudakiI, et al.. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol, 2022, 10(6): 442-456

[15] SheaAK, BuwemboA, MayhewA, et al.. The association between primary ovarian insufficiency and osteoporosis in the Canadian Longitudinal Study on Aging. Menopause (New York, NY), 2021, 28(6): 693-698

[16] KoothirezhiR, RanganathanSPostmenopausal Syndrome. StatPearls, 2022, Treasure Island (FL), StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC

[17] LiuL, LiuY, YangM, et al.. Effectiveness of tonifying-kidney and regulating-liver therapy on diminished ovarian reserve: a systematic review and Meta-analysis of randomized controlled trials. J Trad Chin med, 2020, 40(3): 343-354

[18] ZhaoY, ChenY, MiaoC, et al.. He’s Yangchao Recipe Ameliorates Ovarian Oxidative Stress of Aging Mice under Consecutive Superovulation Involving JNK- And P53-Related Mechanism. eCAM, 2022, 2022: 7705194

[19] YeXW, WangHL, ChengSQ, et al.. Network Pharmacology-Based Strategy to Investigate the Pharmacologic Mechanisms of Coptidis Rhizoma for the Treatment of Alzheimer’s Disease. Front Aging Neurosci, 2022, 14: 890046

[20] WuT, YangX, CongY, et al.. Effects of Qidantang Granule on early stage of diabetic kidney disease in rats. Aging, 2022, 14(11): 4888-4896